Skip to main content
. 2008 Jun 30;155(2):236–243. doi: 10.1038/bjp.2008.253

Figure 5.

Figure 5

Inhibition of vasoactive intestinal peptide (VIP)-induced relaxations with VIP6–28 and pituitary adenylate cyclase-activating polypeptide (PACAP 6–38) in vaginal arteries. Panel (a) shows the effect of the VIP/PACAP antagonist VIP6–28 (10 nM) on the concentration response curve to VIP in vaginal arteries pre-contracted with phenylephrine (PE). Panel (b) is the same as (a), but in the presence of the PAC1 antagonist PACAP 6–38 (1 μM).